Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of the colony-stimulating factors whose name is derived from its major target cell lineages. Since the original studies, which characterized its ability to stimulate the clonal proliferation of myel-oid precursors, however, a broader range of biologic effects on mature, effector cells, and the immune system, have been identified. These expanded areas of activity have carried its more recent clinical application beyond that of ‘colony-stimulating factor’ into the realm of immunomodulation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471–2508.
American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996;14:1957–1960.
Antin JH, Smith BR, Holmes W, Rosenthal DS. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988;72:705–713.
Archimbaud E, Fenaux P, Reiffers J, et al. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia 1993;7:372–377.
Arnout MA, Wang EA, Clark SC, Sieff CA. Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes. J Clin Invest 1986;78:597–601.
Bajorin D, Nichols CR, Schmoll H-J, et al. Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide based chemotherapy for patients with advanced or relapsed germ cell tumors: A randomized trial. J Clin Oncol 1995;13:79–86.
Banchereau J, Briere F, Caux C, et al. Immunology of dendritic cells. Annu Rev Immunol 2000;18:767–811.
Bettelheim P, Valent P, Andreeff M, et al. Recombinant human granulocyte-macrophage colony stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991;77:700–711.
Bishop MR, Anderson JR, Jackson JD, et al. High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 1994;83:610–616.
Blazar BR, Kersey JH, McGlave PB et al. In vivo administration of recombinant human granulocyte/macrophage colony stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood 1989;73:849–857.
Brach MA, deVos S, Gruss HJ, Herrmann F. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. Blood 1992;80:2920–2924.
Brandt SJ, Peters WP, Atwater SK, et al. Effect of recombinant human granulocyte-macrophage colony stimulating factor on hematopoietic reconstitution after high dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988;318:869–876.
Budel LM, Elbaz O, Hoogerbrugge H, et al. Common binding structure for granulocyte macrophage colony-stimulating factor and interleukin-3 on human acute myeloid leukemia cells and monocytes. Blood 1990;75:1439–1445.
Budel LM, Touw IP, Delwel R, Clark SC, Lowenberg B. Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship, to the proliferative response. Blood 1989;74:565–571.
Bunn PA, Crowley J, Kelly K, et al. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995;13:1632–1641.
Burgess AW, Begley CG, Johnson GR, et al. Purification and properties of bacterially synthesized human granulocyte macrophage colony stimulating factor. Blood 1987;69:43–51.
Cannistra SA, DiCarlo J, Groshek P, et al. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1991;5:230–238.
Cannistra SA, Groshek P, Garlick R, et al. Regulation of surface expression of the granulocyte/macrophage colony stimulating factor receptor in normal human myeloid cells. Proc Natl Acad Sci USA 1990;87:97.
Cannistra SA, Rambaldi A, Spriggs DR, Herrmann F, Kufe D, Griffin JD. Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest 1987;79:1720–1728.
Cantrell MA, Anderson D, Ceretti DP, et al. Cloning sequence and expression of human granulocyte/macrophage colony stimulating factor. Proc Natl Acad Sci USA 1985;73:6250–6254.
Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992;360:258–261.
Caux C, Massacrier C, Vanbervliet B, et al. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 1997;90:1458–1470.
Devereux S, Bull HA, Campos-Costa D, et al. Granulocyte macrophage colony stimulating factor induced changes in cellular adhesion molecule expression and adhesion to endothelium: in-vitro and in-vivo studies in man. Br J Haemoto1 1989;71:323–330.
DiPersio J, Billing P, Kaufman S, et al. Characterization of the human granulocyte-macrophage colony-stimulating factor receptor. J Biol Chem 1988;263:1834–1841.
Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, Ferrara JL, Bierer BE, Croop JM. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 1998;91:222–230.
Economopoulos T, Papageorgiou E, Stathakis N, et al. Treatment of myelodysplastic syndromes with human granulocyte-macrophage colony-stimulating factor (GM-CSF) or GM-CSF combined with low-dose cytosine arabinoside. Eur J Haemato1 1999;49:138–142.
Elias AD, Ayash L, Anderson KC, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992;79:3036–3044.
Ellem KA, O'Rourke MG, Johnson GR, et al. A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997;44:10–20.
Estey EH, Kurzrock R, Talpaz M, et al. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol 1991;77:291–295.
Estey E, Thall PF, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C+ daunorubicin: Comparison to patients treated without GM-CSF. Blood 1992;79:2246–2255.
Ganser A, Ottman OG, Erdmann H, et al. The effect of recombinant human granulocyte-macrophage colony-stimulating factor on neu-tropenia and related morbidity in chronic severe neutropenia. Ann Intern Med 1989;111:887–892.
Ganser A, Volkers B, Greher J, et al. Recombinant human granulo-cyte-macrophage colony-stimulating factor in patients with myelo-dysplastic syndromes–A phase I/II trial. Blood 1989;73:31–37.
Gasson JC, Kaufman SE, Weisbart RH, Tomonaga M, Golde DW. High-affinity binding of granulocyte-macrophage colony stimulating factor to normal and leukemic human myeloid cells. Proc Natl Acad Sci USA 1986;83:669–673.
Gasson JC, Weisbart RH, Kaufman SE, et al. Purified human gran-ulocyte-macrophage colony-stimulating factor: Direct action on neutrophils. Science 1984;226:1339–1342.
Gerhartz HH, Engelhard M, Meusers P, et al. Randomized, doubleblind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. Blood 1993;82:2329–2339.
Gianni AM, Bregni M, Stern AC, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating hemopoietic stem cells for autotransplantation. Lancet 1989;580–584.
Gianni AM, Tarella C, Siena S, et al. Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells. Bone Marrow Transplant 1990;6:143–145.
Gosselin EJ, Wardwell K, Rigby WF, Guyre PM. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, INF-gamma and IL-3. J Immunol 1993;151:1482–1490.
Grabstein KH, Urdal DL, Tushinski RJ, et al. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 1986;232:506–508.
Gradishar W, Le Beau MM, O'Laughlin R, et al. Clinical and cyto-genetic responses to GM-CSF in therapy-related myelodysplastic syndrome. Blood 1992;80:2463–2470.
Griffin JD, Spertini O, Ernst TJ, et al. Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors. J lmmunol 1990;145:576–584.
Griffin JD, Young D, Herrmann F, et al. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 1986;67:1448–1453.
Haas R, Ho AD, Bredthauer U, et al. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1990;18:94–98.
Handman E, Burgess AW. Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages. J Immunol 1979;120:1134–1137.
Hart PH, Whitty GA, Piccoli DS, Hamilton JA. Synergistic activation of human monocytes by granulocyt-macrophage colony-stimulating factor and IFN-gamma: Increased TNF-alpha but not IL-1 activity. J Immunol 1988;141:1516–1521.
Hayashida K, Kitamura T, Gorman DM, et al. Molecular cloning of a second subunit of the receptor for human granulocyte-macrophage colony-stimulating factor (GMCSF): Reconstitution of a high-affinity GM-CSF receptor. Proc Natl Acad Sci USA 1990;87:9655–9659.
Heil G, Chadid L, Hoelzer D, et al. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo/acute myeloid leukemia (AML). Leukemia 1995;9:3–9.
Herrlinger U, Kramm CM, Johnston KM, et al. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 1997;4:345–352.
Hermann F, Lindemann A, Klein H, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts. Leukemia 1989;3:335–338.
Herrmann F, Schulz G, Lindemann A, et al. Yeast expressed gran-ulocyte-macrophage colony-stimulating factor in cancer patients: A phase Ib clinical study. Behring Inst Mitt 1988;83:107–118.
Huebner K, Isobe M, Croce CM, et al. The human gene encoding GM-CSF is at 5q21-q32, the chromosome region deleted in the 5q- anomaly. Science 1985;230:1282–1285.
Jaschke E, Zabernigg A, Gattringer C. Recombinant human gran-ulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol 1999;38:380–386.
Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immuno-deficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1999;9:929–940.
Kurzrock R, Talpaz M, Gomez JA, et al. Differential dose-related haematological effects of GM-CSF in pancytopenia: evidence supporting the advantage of low-over high-dose administration in selected patients. Br J Haematol 1991;78:352–358.
Lazarus HM, Andersen J, Chen MG, et al. Recombinant granulo-cyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: Blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group trial. Blood 1991;78:830.
Le Beau MM, Epstein ND, O'Brien SJ, et al. The interleukin 3 gene is located on human chromosome 5 and is deleted in myeloid leukemias with a deletion of 5q. Proc Natl Acad Sci USA 1987;84:5913–5917.
Leong S P, Enders-Zohr P, Zhou YM, et al. Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother 1999;22:166–174.
Lieschke GJ, Maher D, Cebon J, et al. Effects of bacterially synthesized recombinant human granulocyte macrophage colony-stimulating factor in patients with advanced malignancy. Ann Int Med 1989;110:357–364.
Lieschke GJ, Maher D, O'Connor M, et al. Phase I study of intravenously administered bacterially synthesized granulocyte-mac-rophage colony-stimulating factor and comparison with subcutaneous administration. Cancer Res 1990;50:606–614.
Lopez AF, Williamson J, Gamble JR, et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression and survival. J Clin Invest 1986;78:1220–1228.
Metcalf D, Begley CG, Johnson GR, et al. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony stimulating factor. Blood 1986;67:37–45.
Miyauchi J, Kelleher CA, Yang YC, et al. The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood 1987;70:657–663.
Mudzinski SP, Christian TP, Guo TL, Cirenza E, Hazlett KR, Gosselin EJ. Expression of HLA-DR (major histocompatibility complex class II) on neutrophils from patients treated with granulocyte-macrophage colony-stimulating factor for mobilization of stem cells. Blood 1995;86:2452–2453.
Nemunaitis J, Singer JW, Buckner CD, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous marrow transplantation for lymphoid malignancies. Blood 1988;72:834–836.
O'Day SJ, Rabinowe SIN, Neuberg D, et al. A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. Blood 1994;83:2707–2714.
Onetto-Pothier N, Aumont N, Haman A, et al. Characterization of granulocyte-macrophage colony-stimulating factor receptor on the blast cells of acute myeloblastic leukemia. Blood 1990;75:59–66.
Ozer H, Armitage JO, Bennett CL, et al. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 2000;18:3558–85.
Peters WP, Rosner G, Ross M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993;81:1709–1719.
Peters WP, Stuart A, Affronn ML, et al. Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. Blood 1988;72:1310–1315.
Pettenati MJ, Le Beau MM, Lemons RS, et al. Assignment of CSF-1 to 5q33.1: Evidence for the clustering of genes regulating hematopoiesis and for their involvement in the deletion of the long arm of chromosome 5 in myeloid disorders. Proc Natl Acad Sci USA 1987;84:2970–2974.
Quelle FW, Sato N, Witthuhn BA, et al. JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol 1994;14:4335–4341.
Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993;82:2605–2610.
Santoli D, Clark SC, Kreider BL, Maslin PA, Rovera G. Amplification of IL-2-driven T cell proliferative by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J Immunol 1988;141:519–526.
Sato N, Sakamaki K, Terada N, Arai K, Miyajimi A. Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common beta subunit responsible for different signaling. EMBO J 1993;12:4181–4189.
Schaison G, Eden OB, Henze G, et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Pediatr 1998;157:955–966.
Shea TC, Mason JR, Storniolo AM, et al. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 1992;10:464–473.
Sieff C, Emerson SG, Donahue RE, et al. Human recombinant granulocyte-macrophage colony-stimulating factor: a multi-lineage hematopoietin. Science 1985;230:1171–1173.
Siena S, Bregni M, Brando B, et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989;74:1905–1914.
Silberstein DS, Owen WF, Gasson JC, et al. Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol 1986;137:3290–3294.
Socinski MA, Cannistra SA, Sullivan R, et al. Human granulocyte-macrophage colony stimulating factor induces expression of the CD11 b surface adhesion molecule on granulocytes in vivo. Blood 1988;72:691–697.
Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 1998;95:13141–13146.
Steward WP, Scarffe JH, Dirix LY, et al. Granulocyte-macrophage colony stimulating factor (GM-CSF) after high-dose melphalan in patients with advanced colon cancer. Br J Cancer 1990;61:749–754.
Sutherland GR, Baker E, Callen DF, et al. Interleukin-5 is at 5q31 and is deleted in the 5q- syndrome. Blood 1988;71:1150–1152.
Thompson JA, Lee DJ, Kidd P, et al. Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodys-plastic syndromes: Toxicity, pharmacokinetics, and hematologic effects. J Clin Oncol 1989;7:629–637.
Vadhan-Raj S, Keating M, LeMaistre A, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1988;317:1545–1551.
Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD. The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987;69:1771–1776.
Weisbart RH, Golde DW, Clark SC, et al. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature 1985;314:361–363.
Weisbart RH, Golde DW, Gasson JC. Biosynthetic human GM-CSF modulates the number and affinity of neutrophil. F-met-leu-phe receptors. J Immunol 1986;137:3584–3587.
Weiser WY, Van Niel A, Clark SC, et al. Recombinant human granulocyte-macrophage colony-stimulating factor activates intra-cellular killing of Leishmania donovani by human monocyte-derived macrophage. J Exp Med 1987;166:1436–1446.
Welte K, Zeidle C, Reiter A, et al. Differential effects of granulocyte-macrophage colony stimulating factor in children with severe congenital neutropenia. Blood 1990;75:1056–1063.
Williams MA, Kelsey SM, Collins PW, Gutteridge CN, Newland AC. Administration of rHuGM-CSF activates monocyte reactive oxygen species secretion and adhesion molecule expression in vivo in patients following high-dose chemotherapy. Br J Haematol 1995;90:31–40.
Wong GG, Witek JS, Temple PA, et al. Human GM-CSF molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 1985;228:810–815.
Yarden Y, Escobedo JA, Kuang WJ. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. Nature 1986;323:226–232.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Foote, M., Morstyn, G. (2009). Granulocyte-macrophage colony-stimulating factor. In: Oldham, R.K., Dillman, R.O. (eds) Principles of Cancer Biotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-2289-9_18
Download citation
DOI: https://doi.org/10.1007/978-90-481-2289-9_18
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-2277-6
Online ISBN: 978-90-481-2289-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)